J&J Q1 2026 earnings beat estimates with raised FY guidance
Key Questions
What were Johnson & Johnson's Q1 2026 revenue and adjusted EPS results compared to estimates?
Johnson & Johnson reported Q1 revenue of $24.06-24.1 billion, up 9.9% and exceeding estimates. Adjusted EPS was $2.70, also beating expectations.
How did the Innovative Medicine segment perform in Q1 2026?
The Innovative Medicine segment grew 7.4% year-over-year. Oncology sales reached $6.97 billion, up 22.8%, driven by Darzalex, Tremfya, Carvykti, and Tecvayli.
What offset the decline in Stelara sales during Q1?
Stelara sales dropped 60% or 920 basis points due to biosimilar competition. This was offset by strong growth in oncology products like Darzalex and Tremfya.
How did the MedTech segment fare in Q1 2026?
MedTech revenue increased by 4.6-7.7% year-over-year. This contributed to the overall earnings beat.
What is Johnson & Johnson's FY 2026 guidance?
The company raised FY guidance to $100.8 billion in revenue, implying 7% growth, and adjusted EPS of $11.55. This reflects confidence in ongoing performance.
Did Johnson & Johnson increase its dividend, and what is the new amount?
Yes, J&J announced its 64th consecutive annual dividend increase of 3.1% to $1.34 per quarter. This underscores the company's commitment to shareholders.
What was the stock market reaction to the Q1 earnings?
J&J stock showed mixed reactions, rising about 1.26% to around $241 in some sessions. Reactions varied despite the earnings beat and raised guidance.
How did free cash flow perform in Q1 2026?
Free cash flow declined 55% year-over-year. Investors are monitoring future quarters, price targets, and FCF recovery.
Q1 rev $24.06-24.1B +9.9% > est, adj EPS $2.70 > est; Innovative Medicine +7.4% oncology $6.97B +22.8% (Darzalex/Tremfya/Carvykti/Tecvayli) offsets Stelara -60%/-920bps, MedTech +4.6-7.7%; FY guide $100.8B rev +7%/$11.55 EPS; div +3.1% to $1.34/q (64th); FCF -55%; stock mixed reactions (+1.26% to $241); no talc mention. Monitor Q2/PTs/FCF.